ERT CEO Discusses Q3 2010 Results - Earnings Call Transcript
Our forward-looking statements speak only as of the date made. We do not undertake and expressly disclaim any obligation to update forward-looking statements to reflect events or circumstances after the dates of these statements, except as required by law. You are cautioned not to place undue reliance on our forward-looking statements.
In addition to GAAP financial measures, we used certain non-GAAP financial measures that exclude charges related to amortization of the acquired intangible assets and the acquisition and other costs related to the recent acquisition of RS and related income tax effects. A discussion of the use of non-GAAP measures and the reconciliation to GAAP amounts is contained in the press release that we issued this afternoon.
I will first give highlights for the third quarter and details on new bookings and our operations. Keith will then discuss the detailed financials for the quarter. I will then provide some further comments on the business and then open the call up to questions.
The third quarter saw the first full quarter impact of our resent acquisition of RS. This has significantly increased our market opportunity and has given us a much broader set of products and services to offer to the clinical trials industry and potentially in the future to the healthcare industry.Specifically, we now have an industry leading suite of products in respiratory diagnostics for clinical trials that encompass the primary respiratory diseases of COPD, asthma, and cystic fibrosis. We have added significant additional capabilities to our ePRO product and service lines by adding a PDA like device VIAPad as well as a pen based device VIAPen. We have also added a whole dimension to the products and services that we can offer our own proprietary diagnostic devices for clinical trials. These devices give us an expanded approach to offer and customize product solutions using multiple modalities for the acquisition of important information in clinical trials. We believe this offers us a key strategic competitive advantage in our industry.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV